After the Trust Shock: A High-Quality Franchise at a Rare Discount

Over the past twelve months, Boston Scientific shares have ranged from roughly $49 to $109.50—a drawdown of more than 50% from peak to the recent trading range around the low $50s. That is an extraordinary move for what remains one of the most diversified med-tech platforms in the world.

The proximate causes are well catalogued:

Guidance cut. Management slashed full-year 2026 organic growth guidance from an initial 10%–11% range down to 6.5%–8.0% during its April Q1 earnings call. CEO Mike Mahoney attributed the revision to headwinds in WATCHMAN, electrophysiology, and urology.

WATCHMAN deceleration. After WATCHMAN delivered 29% sales growth in 2025, standalone procedure volumes softened as Q1 progressed. Management now expects roughly flat WATCHMAN dollar growth from Q1 to Q2 and likely from Q2 to Q3.

EP competitive pressure. In electrophysiology, Boston Scientific ceded more market share than anticipated. Johnson & Johnson's Varipulse system—integrated with the dominant CARTO mapping platform—created meaningful switching costs for physicians, making competitive inroads.

Urology softness. The urology business barely grew, expanding roughly 2% year-over-year to $646 million, well below expectations. Management acknowledged it will grow below the company's typical pace in 2026.

Recall headline risk. The FDA issued a Class I recall correction for certain ACCOLADE pacemakers due to a software-related battery issue that could lead to serious injury or death.

Then, at Bernstein's Annual Strategic Decisions Conference on May 27, management reiterated—rather than upgraded—its lowered growth expectations and confirmed that standalone WATCHMAN procedure volumes continued to decline. Shares closed at $50.42, down 12.53%.

The sum of it: the market no longer prices Boston Scientific as an insulated compounder. The question for investors is whether the de-rating has overshot reality....